

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7427814

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SEQUENCE:	1	
CONVEYING PARTY DATA		
	Name	Execution Date
	NAPA MEDICAL RESEARCH FOUNDATION	07/08/2022
RECEIVING PARTY DATA		
Name:	DREGALLA MEDICAL TECHNOLOGIES	
Street Address:	5675 SUMMERLYN CT	
City:	WINDSOR	
State/Country:	COLORADO	
Postal Code:	80550	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Patent Number:	11253548
	Application Number:	17672132
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	7209794464	
Email:	tim.n.snyder@gmail.com	
Correspondent Name:	TIMOTHY SNYDER	
Address Line 1:	15701 VILLAGE CIR	
Address Line 4:	COMMERCE CITY, COLORADO 80603	
NAME OF SUBMITTER:	TIMOTHY SNYDER	
SIGNATURE:	/Timothy Snyder/	
DATE SIGNED:	07/12/2022	
Total Attachments: 3		
source=NMRF-DMT#page1.tif		
source=NMRF-DMT#page2.tif		
source=NMRF-DMT#page3.tif		

ASSIGNMENT AGREEMENT

THIS ASSIGNMENT, made this 8th day of July, 2022 by and between Napa Medical Research Foundation a 501(c)(3) nonprofit corporation organized under and pursuant to the laws of California, having its principal place of business at 3421 Villa Lane, Suite 2C, Napa, California, 94558, United States of America (hereinafter referred to as Assignor), and Dregalla Medical Technologies LLC, a Limited Liability Company organized under and pursuant to the laws of Colorado, having its principal place of business at 5675 Summerlyn Ct., Windsor, Colorado, 80550, United States of America (hereinafter referred to as Assignee);

WHEREAS, Assignor is the sole and exclusive owner of the U.S. Letters Patents and pending patent applications identified as:

- **METHOD OF PRODUCING THE CONSTITUENTS OF A THERAPEUTIC PRODUCT FROM MAMMALIAN CELLS**, set forth in a United States Non-Provisional Application which was filed on March 11th, 2019, under Serial No. 16/298,669, now Patent No. 11,253,548; and
- **PRODUCTS DERIVED FROM MAMMALIAN CELLS**, set forth in a United States Non-Provisional Application which was filed on February 15th, 2022, under Serial No. 17/672,132, and which is a continuation-in-part of United States Patent Application No. 16/298,669;

WHEREAS, Assignee, is desirous of acquiring the entire right, title, and interest in and to said inventions and said Applications for Letters Patent of the United States, and in and to any Letters Patents of the United States as may be obtained therefor and thereon, or any Letters Patent as may issue in continuation therefrom, in the United States or in any other jurisdiction in the world,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and

assigns, the entire right, title and interest in and to the above-mentioned inventions, applications for Letters Patent, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said applications, and any and all Letters Patent in the United States and all foreign countries which may be granted therefor and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

AND for the same consideration, Assignor hereby represents and warrants to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignor is the sole and lawful owner of the entire right, title and interest in and to the said inventions and application for Provisional or Letters Patent above-mentioned, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns, that Assignor will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Provisional or Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Provisional or Letters Patent, or any proceeding in connection with any Letters Patent or applications for Provisional or Letters Patent for said inventions in any country, including but not limited to interference proceedings, is lawful and desirable, or, that any division, continuation or continuation-in-part of any application for Provisional or Letters Patent, or any reissue, reexamination or extension of any Provisional or Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignor hereby requests the Commissioner of Patent and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, this Assignment has been duly executed on the day and year first above written.

Napa Medical Research Foundation

By:



Brad Varton
Executive Director